ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of “Buy” by Brokerages

ProQR Therapeutics (NASDAQ:PRQR) has earned a consensus rating of “Buy” from the six brokerages that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $8.83.

Several equities analysts recently weighed in on PRQR shares. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th. StockNews.com lowered shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $6.00 to $14.00 in a report on Tuesday, October 29th. Chardan Capital reaffirmed a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Finally, Oppenheimer began coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They issued an “outperform” rating and a $15.00 price target on the stock.

ProQR Therapeutics Stock Performance

Shares of PRQR opened at $2.20 on Friday. ProQR Therapeutics has a 1 year low of $1.61 and a 1 year high of $4.62. The company’s 50 day simple moving average is $2.72 and its 200 day simple moving average is $2.58. The company has a market capitalization of $179.70 million, a price-to-earnings ratio of -6.88 and a beta of 0.26.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%. The company had revenue of $4.22 million for the quarter, compared to analyst estimates of $4.75 million. Equities analysts expect that ProQR Therapeutics will post -0.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PRQR. BNP Paribas Financial Markets raised its stake in shares of ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 7,300 shares during the period. OneDigital Investment Advisors LLC boosted its position in shares of ProQR Therapeutics by 37.0% in the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 15,550 shares during the period. Ballentine Partners LLC purchased a new stake in shares of ProQR Therapeutics in the fourth quarter worth about $61,000. Finally, Privium Fund Management B.V. grew its stake in shares of ProQR Therapeutics by 0.9% in the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after buying an additional 51,663 shares in the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).